Statins may increase the risk of being diagnosed with prostate cancer.

IF 4.9 2区医学 Q1 UROLOGY & NEPHROLOGY Minerva Urology and Nephrology Pub Date : 2024-02-01 Epub Date: 2023-10-05 DOI:10.23736/S2724-6051.23.05454-X

Aldo Brassetti, Francesco Tedesco, Loris Cacciatore, Francesco Prata, Alberto Ragusa, Andrea Iannuzzi, Riccardo Lombardo, Giorgia Tema, Antonio Cicione, Andrea Tubaro, Giuseppe Simone, Cosimo DE Nunzio

{"title":"Statins may increase the risk of being diagnosed with prostate cancer.","authors":"Aldo Brassetti, Francesco Tedesco, Loris Cacciatore, Francesco Prata, Alberto Ragusa, Andrea Iannuzzi, Riccardo Lombardo, Giorgia Tema, Antonio Cicione, Andrea Tubaro, Giuseppe Simone, Cosimo DE Nunzio","doi":"10.23736/S2724-6051.23.05454-X","DOIUrl":null,"url":null,"abstract":"Background: Although statins are known to protect against cardiovascular accidents, their anti-inflammatory features could play a role in preventing tumorigenesis. We investigated the association between statin intake and prostate cancer (PCa) diagnosis and aggressiveness.Methods: A retrospective analysis was performed. Our dataset on patients undergone systematic prostate biopsy from December 2008 to December 2022 was searched for histopathologic and clinical data. Prognostic Grade Group ≥3 tumors were defined as high-grade (HG). The association between Metabolic Syndrome (MetS), statin use and PCa diagnosis and HG disease was assessed using logistic regression analyses.Results: Data on 1685 patients were collected; MetS affected 344 (20.4%) men and 138 (36.5%) were taking statins at least for 6 months at the time of biopsy. Among the 671 (39.8%) men diagnosed with PCa, 327 (48.7%) presented with a HG disease. Tumor incidence was higher among men taking statins, compared to controls (46.8% vs. 37.8%; P=0.002); also, high grade diseases were more common in the former group, but the difference did not reach statistical significance (49.1% vs. 48.6%; P=0.89). Statin intake (OR 1.44; 95% CI [1.05-1.98]; P=0.02) independently predicted PCa diagnosis but not high-grade disease (P=0.8).Conclusions: Statin use may be associated with an increased risk of PCa diagnosis.","PeriodicalId":53228,"journal":{"name":"Minerva Urology and Nephrology","volume":" ","pages":"74-80"},"PeriodicalIF":4.9000,"publicationDate":"2024-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Minerva Urology and Nephrology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.23736/S2724-6051.23.05454-X","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2023/10/5 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Although statins are known to protect against cardiovascular accidents, their anti-inflammatory features could play a role in preventing tumorigenesis. We investigated the association between statin intake and prostate cancer (PCa) diagnosis and aggressiveness.

Methods: A retrospective analysis was performed. Our dataset on patients undergone systematic prostate biopsy from December 2008 to December 2022 was searched for histopathologic and clinical data. Prognostic Grade Group ≥3 tumors were defined as high-grade (HG). The association between Metabolic Syndrome (MetS), statin use and PCa diagnosis and HG disease was assessed using logistic regression analyses.

Results: Data on 1685 patients were collected; MetS affected 344 (20.4%) men and 138 (36.5%) were taking statins at least for 6 months at the time of biopsy. Among the 671 (39.8%) men diagnosed with PCa, 327 (48.7%) presented with a HG disease. Tumor incidence was higher among men taking statins, compared to controls (46.8% vs. 37.8%; P=0.002); also, high grade diseases were more common in the former group, but the difference did not reach statistical significance (49.1% vs. 48.6%; P=0.89). Statin intake (OR 1.44; 95% CI [1.05-1.98]; P=0.02) independently predicted PCa diagnosis but not high-grade disease (P=0.8).

Conclusions: Statin use may be associated with an increased risk of PCa diagnosis.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

他汀类药物可能会增加被诊断为前列腺癌症的风险。

背景：尽管他汀类药物可以预防心血管事故，但其抗炎特性可能在预防肿瘤发生方面发挥作用。我们研究了他汀类药物摄入与前列腺癌症（PCa）诊断和侵袭性之间的关系。方法：回顾性分析。我们对2008年12月至2022年12月接受系统前列腺活检的患者的数据集进行了组织病理学和临床数据搜索。预后分级组≥3个肿瘤被定义为高级别（HG）。使用逻辑回归分析评估代谢综合征（MetS）、他汀类药物的使用和PCa诊断与HG疾病之间的关系。结果：收集了1685例患者的资料；MetS影响344名（20.4%）男性，138名（36.5%）男性在活检时至少服用他汀类药物6个月。在671名（39.8%）被诊断为前列腺癌的男性中，327名（48.7%）患有HG疾病。与对照组相比，服用他汀类药物的男性肿瘤发生率更高（46.8%对37.8%；P=0.002）；此外，高级别疾病在前一组中更常见，但差异没有达到统计学意义（49.1%vs.48.6%；P=0.89）。他汀类药物的摄入（OR 1.44；95%CI[1.05-1.98]；P=0.02）独立预测PCa诊断，但不预测高级别疾病（P=0.8）。结论：他汀类药物使用可能与PCa诊断风险增加有关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊